Home › Multiple Sclerosis › Arizona › Phoenix
Multiple Sclerosis clinical trials in Phoenix, AZ
3 studies for Multiple Sclerosis are looking for participants at sites in and around Phoenix (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
RecruitingObservational study
- TG Therapeutics Investigational Trial Site, Phoenix
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RecruitingPhase 3
- Center for Neurology and Spine - Phoenix - East Bell Road- Site Number : 8400195, Phoenix
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
RecruitingPhase 3
- Ctr for Neurology and Spine, Phoenix
- AZ Integrated Neuro and Spine, Phoenix
About Multiple Sclerosis
Multiple sclerosis (MS) slows down or blocks messages between the brain and body. MS can be mild or severe. Learn about MS symptoms and treatment.
More about Multiple Sclerosis on MedlinePlus
Multiple Sclerosis trials in other cities
- New York City, NY17 studies
- Chicago, IL15 studies
- Boston, MA14 studies
- Washington, DC13 studies
- Cleveland, OH9 studies
- St. Louis, MO8 studies
- Kansas City, KS8 studies
- Birmingham, AL8 studies
- San Francisco, CA8 studies
- Columbus, OH7 studies
- Aurora, CO7 studies
- Baltimore, MD7 studies
Other studies in Phoenix
- Breast Cancer25 studies
- Colorectal Cancer25 studies
- Obesity22 studies
- Non-Small Cell Lung Cancer20 studies
- Metastatic Cancer20 studies
- Heart Failure18 studies
- Prostate Cancer17 studies
- Cancer (all types)17 studies
- Multiple Myeloma16 studies
- Pancreatic Cancer16 studies
- Cardiovascular Disease16 studies
- Alzheimer's Disease15 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.